Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 881000

Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars


Inotai, András; Prins, Christiaan; Csanádi, Marcell; Vitezić, Dinko; Codreanu, Catalin; Kaló, Zoltán
Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars // Expert opinion on biological therapy, 17 (2017), 8; 915-926 doi:10.1080/14712598.2017.1341486 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 881000 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars

Autori
Inotai, András ; Prins, Christiaan ; Csanádi, Marcell ; Vitezić, Dinko ; Codreanu, Catalin ; Kaló, Zoltán

Izvornik
Expert opinion on biological therapy (1471-2598) 17 (2017), 8; 915-926

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
biosimilar ; immunogenicity ; patient access ; risk ; societal benefit ; substitution ; switch

Sažetak
Introduction: While prescribing biosimilars to patients naive to a biologic treatment is a well- accepted practice, switching clinically stable patients from an originator to a biosimilar is an issue for clinicians. Well designed clinical trials and real-world data which study the consequences of switching from an originator biologic treatment to its biosimilar alternative are limited, especially for monoclonal antibodies. Areas covered: A systematic literature review was conducted on PubMed to identify evidence of the consequences of switching from original biologics to biosimilars. References of included papers were also scrutinized. After a title-, abstract- and full text screening, out of the 153 original hits and 77 additional ones from screening the references, 58 papers (12 empirical papers, 5 systematic reviews and 41 non-empirical papers) were included. Expert opinion: Preventing patients on biologic medicines from switching to biosimilars due to anticipated risks seems to be disproportional compared to the expected cost savings and/or improved patient access. Indeed, it is the opinion of the authors that the concern of switching to biosimilars is overhyped.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Projekti:
MZOS-062-0620063-0060 - Uporaba kardiovaskularnih lijekova i značaj farmakoekonomskih procjena (Vitezić, Dinko, MZOS ) ( CroRIS)

Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka

Profili:

Avatar Url Dinko Vitezić (autor)

Poveznice na cjeloviti tekst rada:

doi www.tandfonline.com

Citiraj ovu publikaciju:

Inotai, András; Prins, Christiaan; Csanádi, Marcell; Vitezić, Dinko; Codreanu, Catalin; Kaló, Zoltán
Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars // Expert opinion on biological therapy, 17 (2017), 8; 915-926 doi:10.1080/14712598.2017.1341486 (međunarodna recenzija, članak, znanstveni)
Inotai, A., Prins, C., Csanádi, M., Vitezić, D., Codreanu, C. & Kaló, Z. (2017) Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Expert opinion on biological therapy, 17 (8), 915-926 doi:10.1080/14712598.2017.1341486.
@article{article, author = {Inotai, Andr\'{a}s and Prins, Christiaan and Csan\'{a}di, Marcell and Vitezi\'{c}, Dinko and Codreanu, Catalin and Kal\'{o}, Zolt\'{a}n}, year = {2017}, pages = {915-926}, DOI = {10.1080/14712598.2017.1341486}, keywords = {biosimilar, immunogenicity, patient access, risk, societal benefit, substitution, switch}, journal = {Expert opinion on biological therapy}, doi = {10.1080/14712598.2017.1341486}, volume = {17}, number = {8}, issn = {1471-2598}, title = {Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars}, keyword = {biosimilar, immunogenicity, patient access, risk, societal benefit, substitution, switch} }
@article{article, author = {Inotai, Andr\'{a}s and Prins, Christiaan and Csan\'{a}di, Marcell and Vitezi\'{c}, Dinko and Codreanu, Catalin and Kal\'{o}, Zolt\'{a}n}, year = {2017}, pages = {915-926}, DOI = {10.1080/14712598.2017.1341486}, keywords = {biosimilar, immunogenicity, patient access, risk, societal benefit, substitution, switch}, journal = {Expert opinion on biological therapy}, doi = {10.1080/14712598.2017.1341486}, volume = {17}, number = {8}, issn = {1471-2598}, title = {Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars}, keyword = {biosimilar, immunogenicity, patient access, risk, societal benefit, substitution, switch} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font